| 000 | 01453 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518042633.0 | ||
| 264 | 0 | _c20200114 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a2211-0356 | ||
| 024 | 7 |
_a10.1016/j.msard.2019.05.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBuard, Géraldine | |
| 245 | 0 | 0 |
_aSwitching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. _h[electronic resource] |
| 260 |
_bMultiple sclerosis and related disorders _c08 2019 |
||
| 300 |
_a39-43 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aCrotonates _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlatiramer Acetate _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydroxybutyrates |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aToluidines _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGiovannelli, Jonathan | |
| 700 | 1 | _aOutteryck, Olivier | |
| 700 | 1 | _aHadhoum, Nawal | |
| 700 | 1 | _aLannoy, Julien | |
| 700 | 1 | _aVermersch, Patrick | |
| 700 | 1 | _aZéphir, Hélène | |
| 773 | 0 |
_tMultiple sclerosis and related disorders _gvol. 33 _gp. 39-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.msard.2019.05.015 _zAvailable from publisher's website |
| 999 |
_c29753372 _d29753372 |
||